MA51036A - Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4 - Google Patents
Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4Info
- Publication number
- MA51036A MA51036A MA051036A MA51036A MA51036A MA 51036 A MA51036 A MA 51036A MA 051036 A MA051036 A MA 051036A MA 51036 A MA51036 A MA 51036A MA 51036 A MA51036 A MA 51036A
- Authority
- MA
- Morocco
- Prior art keywords
- acetylcholin
- muscarinic
- receptor
- positive allosteric
- allosteric modulators
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762594753P | 2017-12-05 | 2017-12-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA51036A true MA51036A (fr) | 2021-03-17 |
Family
ID=64902427
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA051036A MA51036A (fr) | 2017-12-05 | 2018-12-05 | Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4 |
Country Status (6)
Country | Link |
---|---|
US (1) | US11376254B2 (fr) |
EP (1) | EP3720859A1 (fr) |
JP (1) | JP2021505581A (fr) |
CN (1) | CN111406058A (fr) |
MA (1) | MA51036A (fr) |
WO (1) | WO2019113174A1 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20180114B1 (ar) * | 2016-06-22 | 2022-09-15 | Univ Vanderbilt | عوامل تعديل متباينة التجاسم موجبة من مستقبل الأسيتيل كولين المسكاريني m4 |
WO2023114224A1 (fr) | 2021-12-13 | 2023-06-22 | Sage Therapeutics, Inc. | Combinaison de modulateurs positifs du récepteur muscarinique et de modulateurs allostériques positifs de nmda |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5594001A (en) | 1993-04-08 | 1997-01-14 | The Dupont Merck Pharmaceutical Company | Polycyclic systems, and derivatives thereof, as neurotransmitter release enhancers useful in the treatment of cognitive disorders |
IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
US5679683A (en) | 1994-01-25 | 1997-10-21 | Warner-Lambert Company | Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
AU2001231154A1 (en) | 2000-01-24 | 2001-07-31 | Adherex Technologies Inc. | Peptidomimetic modulators of cell adhesion |
US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
US20040235809A1 (en) | 2000-07-27 | 2004-11-25 | Alexander John C | Epoxy steroidal aldosterone antagonist and beta-adremergic antagonist combination therepy for treatment of congestive heart failure |
US7291733B2 (en) * | 2003-10-10 | 2007-11-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted tricyclic heterocycles and their uses |
US20090099165A1 (en) | 2003-10-14 | 2009-04-16 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Protein Kinase Inhibitors |
PL1678166T3 (pl) | 2003-10-14 | 2009-12-31 | Univ Arizona | Inhibitory kinaz białkowych |
AR049300A1 (es) | 2004-06-15 | 2006-07-12 | Schering Corp | Compuestos triciclicos antagonistas de mglur1 como agentes terapeuticos |
EP1619196A1 (fr) * | 2004-07-23 | 2006-01-25 | Curacyte Discovery GmbH | Pyrido[3',2':4,5]thieno[3,2-d]pyrimidines et Pyrido[3',2':4,5]furo[3,2-d]-pyrimidines substitués comme inhibiteurs de PDA-4 et/ou libération de TNF-alpha |
ES2341559T3 (es) | 2004-07-23 | 2010-06-22 | The Medicines Company (Leipzig) Gmbh | Pirido(3',2':4,5)tieno(3,2-d)pirimidinas y pirido(3',2':4,5)furo(3,2-d)pirimidinas sustituidas para su utilizacion como inhibidores de la liberacion de pda-4 y/o tnf-alfa. |
BRPI0517438A (pt) | 2004-10-25 | 2008-10-07 | Lilly Co Eli | composto, método para tratar a condição associada com atividade de receptor muscarìnico m4, uso do composto, e, composição farmacêutica |
ES2259891B1 (es) | 2004-11-30 | 2007-11-01 | Laboratorios Almirall S.A. | Nuevos derivados de piridotienopirimidina. |
ES2259892B1 (es) | 2004-11-30 | 2007-11-01 | Laboratorios Almirall S.A. | Nuevos derivados de piridotienopirimidina. |
WO2006138418A2 (fr) | 2005-06-14 | 2006-12-28 | President And Fellows Of Harvard College | Amelioration de la performance cognitive avec des activateurs de sirtuine |
AR059901A1 (es) | 2006-03-20 | 2008-05-07 | Bayer Pharmaceuticals Corp | Compuestos de tetrahidropiridotienopirimidina utiles para tratar o prevenir trastornos proliferativos celulares. |
US20080021063A1 (en) | 2006-07-18 | 2008-01-24 | Kazantsev Aleksey G | Compositions and methods for modulating sirtuin activity |
US7547781B2 (en) | 2006-09-11 | 2009-06-16 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
EP2476679B1 (fr) | 2006-12-29 | 2015-10-14 | Rigel Pharmaceuticals, Inc. | Triazoles substitués utilisés comme inhibiteurs AXL |
US20090105240A1 (en) | 2007-10-17 | 2009-04-23 | Tomas Mustelin | Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same |
US20100009934A1 (en) | 2008-06-09 | 2010-01-14 | Combinatorx, Incorporated | Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders |
IN2012DN01325A (fr) | 2009-08-20 | 2015-06-05 | Karus Therapeutics Ltd | |
US20110178107A1 (en) | 2010-01-20 | 2011-07-21 | Taigen Biotechnology Co., Ltd. | Hcv protease inhibitors |
WO2012131297A1 (fr) | 2011-03-28 | 2012-10-04 | Jonathan Bayldon Baell | Dérivés de pyrido[3',2':4,5]thiéno[3,2-d]pyrimidin-4-ylamine et leur utilisation thérapeutique |
US9056876B2 (en) * | 2011-09-16 | 2015-06-16 | Vanderbilt University | Substituted 1H-pyrazolo[3′,4′,4,5]thieno[2,3-b]pyridin-3-amine analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M4 |
US20130116241A1 (en) | 2011-11-09 | 2013-05-09 | Abbvie Inc. | Novel inhibitor compounds of phosphodiesterase type 10a |
US9353121B2 (en) | 2011-12-21 | 2016-05-31 | The Regents Of The University Of Colorado, A Body Corporate | Anti-cancer compounds targeting Ral GTPases and methods of using the same |
US8697888B2 (en) | 2012-01-06 | 2014-04-15 | Vanderbilt University | Substituted (1-(methylsulfonyl)azetidin-3-yl)(heterocycloalkyl)methanone analogs as antagonists of muscarinic acetylcholine M1 receptors |
WO2013126856A1 (fr) * | 2012-02-23 | 2013-08-29 | Vanderbilt University | Analogues de 5-aminothiéno[2,3-c]pyridazine-6-carboxamide substitués en tant que modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4 |
EP2872144A4 (fr) | 2012-07-11 | 2015-12-02 | Nimbus Iris Inc | Inhibiteurs d'irak et leurs utilisations |
US9056875B2 (en) * | 2012-08-31 | 2015-06-16 | Vanderbilt University | Substituted pyrazolo[3′,4′:4,5]thieno[2,3-C]pyridazin-3-amine analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M4 |
US9637498B2 (en) * | 2013-08-23 | 2017-05-02 | Vanderbilt University | Substituted thieno[2,3-C]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M4 |
US20160200733A1 (en) | 2013-08-23 | 2016-07-14 | Vanderbilt University | Substituted thieno[2,3-b]pyridine-2-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4 |
US9981920B2 (en) | 2014-06-26 | 2018-05-29 | Rodin Therapeutics, Inc. | Inhibitors of histone deacetylase |
JOP20180114B1 (ar) | 2016-06-22 | 2022-09-15 | Univ Vanderbilt | عوامل تعديل متباينة التجاسم موجبة من مستقبل الأسيتيل كولين المسكاريني m4 |
-
2018
- 2018-12-05 JP JP2020530594A patent/JP2021505581A/ja active Pending
- 2018-12-05 US US16/769,684 patent/US11376254B2/en active Active
- 2018-12-05 MA MA051036A patent/MA51036A/fr unknown
- 2018-12-05 EP EP18829589.3A patent/EP3720859A1/fr not_active Withdrawn
- 2018-12-05 CN CN201880076550.8A patent/CN111406058A/zh active Pending
- 2018-12-05 WO PCT/US2018/064017 patent/WO2019113174A1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
WO2019113174A1 (fr) | 2019-06-13 |
JP2021505581A (ja) | 2021-02-18 |
US11376254B2 (en) | 2022-07-05 |
EP3720859A1 (fr) | 2020-10-14 |
US20200323857A1 (en) | 2020-10-15 |
CN111406058A (zh) | 2020-07-10 |
WO2019113174A8 (fr) | 2020-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA45463A (fr) | Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4 | |
MA44253A (fr) | Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m1 | |
IL273924A (en) | Muscarinic acetylcholine M4 receptor antagonists | |
IL274369A (en) | Combined pressure pathway modulators | |
DK3452448T3 (da) | Modulatorer af den integrerede stressvej | |
IL274405A (en) | Combined pressure pathway modulators | |
IL274368A (en) | Combined pressure pathway modulators | |
MA43756A (fr) | Modulateurs allostériques des récepteurs nicotiniques de l'acétylcholine | |
MA47127A (fr) | Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4 | |
MA46899A (fr) | Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4 | |
IL274367A (en) | Combined pressure pathway modulators | |
MA47126A (fr) | Modulateurs allostériques positifs du récepteur muscarinique à l'acétylcholine m4 | |
MA46722A (fr) | Modulateurs allostériques positifs du récepteur muscarinique à l'acétylcholine m4 | |
IL264951B (en) | Positive allosteric modulators of the m1 muscarinic receptor | |
IL291029A (en) | New modulators of 5-hydroxytryptamine receptor 7 and a method of using them | |
IL274062A (en) | Muscarinic acetylcholine M4 receptor antagonists | |
EP3393472A4 (fr) | Modulateurs allostériques de type 3-(1h-pyrazol-4-yl)pyridine du récepteur muscarinique m4 d'acétylcholine | |
BR112017026561A2 (pt) | moduladores alostéricos positivos do receptor muscarínico m2 | |
IL271805A (en) | M4 muscarinic acetylcholine receptor antagonists | |
EP3697781C0 (fr) | Antagonistes du récepteur muscarinique de l'acétylcholine m4 | |
MA52555A (fr) | Modulateurs du récepteur des oestrogènes | |
MA52482A (fr) | Modulateurs allostériques de spiropipéridine des récepteurs nicotiniques de l'acétylcholine | |
MA51036A (fr) | Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4 | |
HUE036698T2 (hu) | Mérõeszközök regisztrálása az interneten keresztül | |
MA51037A (fr) | Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4 |